Alfuzocine XL a day
ApprovedSmall molecule
Alfuzocine XL a day is one of 2 small molecule programs targeting Ureterolithiasis. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Ureterolithiasis
#DrugCompanyPhaseTrials
1Flomax
SanofiApproved
Alfuzocine XL a day
HHaEmek Medical Center, Israel
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Ureterolithiasis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Alfuzocine XL a day. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- HHaEmek Medical Center, Israel